A therapeutic antagonistic monoclonal antibody, which targets GFRAL and inhibits RET signaling by preventing the GDF15-driven interaction of RET with GFRAL on the cell surface, successfully prevented cancer cachexia [29]. Here, GFRAL is linked to cancer.